Navigation Links
Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
Date:8/20/2007

SAN DIEGO, Aug. 20 /PRNewswire-FirstCall/ -- Lpath, Inc. (OTC Bulletin Board: LPTN), the category leader in therapeutic agents against bioactive lipids, reported that a standard panel of safety tests was recently completed with the humanized version of Sphingomab(TM), and the findings indicate no safety concern for systemic dosing of the antibody to humans.

Sphingomab, generated by Lpath's proprietary ImmuneY2(TM) platform technology, is a monoclonal antibody against the bioactive lipid S1P (sphingosine-1-phosphate). S1P has been well validated as a stimulator of angiogenesis (new blood-vessel growth), a process that has been strongly implicated in the pathology of both cancer and AMD.

The safety tests included cardiovascular studies in Cynomolgus monkeys as well as tests to evaluate the potential of the antibody to elicit the release of cytokines or an Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) reaction. The cardiovascular study included evaluation of the effect of humanized Sphingomab treatment on blood pressure, heart rate, and respiratory rate. The cardiovascular, cytokine release, and ADCC tests with humanized Sphingomab were all negative at doses or concentrations well above those expected to be needed in man to provide an anti-angiogenic action.

The panel of tests also included a pivotal multiple-dosing 28-day study in Cynomolgus monkeys. This study featured intravenous administration of humanized Sphingomab at doses as great as 100 mg/kg every three days for 28 days (10 total doses). Parameters monitored during this study included mortality, body weight, organ weight, clinical observations, ophthalmology, clinical pathology (hematology, clinical chemistry, coagulation, and urinalysis), and immune-phenotyping, both pre-treatment and on day 28 in all animals, and after one, two, three, and four weeks of recovery in a large sub- group of the animals.

No animal deaths occurred during the study. There were also no signific
'/>"/>

SOURCE Lpath, Inc.

Copyright©2007 PR Newswire.

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Lpath Demonstrates First-in-Class AMD Results With Its Lead Drug Candidate, Sphingomab
2. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
3. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
4. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
7. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
8. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
9. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
10. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
11. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...M, N.C., Nov. 6 Oxygen B...day announced that a previously approved reverse s...tart of trading on Monday, Nov. 9, 2009 on a 1-for...Inc. shares will trade under the new symbol OXBT. ...P 20 9, when the split becomes effective. ,, "T...
(Date:11/6/2009)..., FORT WASHINGTON, Pa., Nov. 6 ...stration (FDA), McNeil Consumer Healthcare, Divisi...recall of a limited number of product lots of TYLE... with the distinctive red EZ-OPEN CAP. McNeil is i...teristic smell or taste associated with these lots...
(Date:11/6/2009)...IEGO, Nov. 6 Trius Therapeutics, I...on statement on Form S-1 with the U.S. Securities ...ed initial public offering of shares of its common...in the offering will be offered by the Company. ,...s sole book-running manager, Piper Jaffray & C...
Breaking Medicine Technology:Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009 2Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009 3McNeil Consumer Healthcare Announces Voluntary Recall of Certain Lots of TYLENOL(R) Arthritis Pain 100 Count with EZ-OPEN CAP 2Health Enhancement Products Reacquires ProAlgaZyme 28TM 29 Distribution and Marketing Rights 58753 1Health Enhancement Products Reacquires ProAlgaZyme 28TM 29 Distribution and Marketing Rights 58753 2American Lung Association of Florida South Area Encourages Miami Residents to See Themselves Among the Many Faces of Influenza 58749 1American Lung Association of Florida South Area Encourages Miami Residents to See Themselves Among the Many Faces of Influenza 58749 2American Lung Association of Florida South Area Encourages Miami Residents to See Themselves Among the Many Faces of Influenza 58749 3American Lung Association of Florida South Area Encourages Miami Residents to See Themselves Among the Many Faces of Influenza 58749 4American Lung Association of Florida South Area Encourages Miami Residents to See Themselves Among the Many Faces of Influenza 58749 5R 26amp 3BD Leverage Heightens Investment in Medical and Silicone Mold Manufacturing 58745 1R 26amp 3BD Leverage Heightens Investment in Medical and Silicone Mold Manufacturing 58745 2R 26amp 3BD Leverage Heightens Investment in Medical and Silicone Mold Manufacturing 58745 3
(Date:11/9/2009)... , SAN DIEGO, Nov. 9 , , W...ree pet nutrition, workshop facilitat... experts on Saturday, November 14 at 2 p.m. ...parents will learn about the nutritional needs of,...o discuss the benefits of, good pet n...
(Date:11/9/2009)... , St. Jude Children,s Research Hospital and the ...e formed a collaboration to provide proton therapy...he approval of the first clinical study to evaluat... in children younger than 3 years old. , Under...ts to receive proton therapy at the UF Proton Ther...
(Date:11/9/2009)... , Arnhem, November 2009 The December issue of ...opean Association of Urology, features an article ...ile Men? Results of a Prospective Case-Control Sur...s that male factor infertility is associated with ...scored with the hospital-based Charlson Comorbidit...
(Date:11/9/2009)... , , Blacksburg, Va. In the construction industr...y or an increased risk of cancer, is a major publi...rbett, a faculty member in Virginia Tech,s School ... sanding tools are highly effective in reducing th...ndustry,s usage of the available technology remain...
(Date:11/9/2009)... , Irvine, Calif., Nov. 9, 2009 The first human ...for human testing has been shown to restore limb f...finding that could expand the clinical trial to in... the U.S. Food & Drug Administration gave Geron Co...UC Irvine treatment in individuals with thoracic s...
Breaking Medicine News(10 mins):Health News:St. Jude and UF Proton Therapy Institute to begin proton therapy clinical trial 2Health News:European Urology: Male factor infertility associated with comorbidities 2Health News:Dust control research leads to a NIOSH grant to facilitate adoption of hazard controls 2Health News:Dust control research leads to a NIOSH grant to facilitate adoption of hazard controls 3Health News:UCI embryonic stem cell therapy restores walking ability in rats with neck injuries 2
...ers at the University of Edinburgh have shown that... patients, giving women a new hope. The stud...s proved for the first time that the targeted use ... hormone therapy already used with great success ...
...rado Springs community of U.S is waiting with bate... see if any person has contracted TB from a young...ording to health officials, tuberculosis has been ...o Dr. Ned Calonge, chief medical officer for the C...
...ardly surprising when a Dutch TV network decided t...nth and air a TV reality show featuring a dying wo...e to China, tens of thousands of kidney sufferers ...nsplants, and even in wealthier Europe, 10 deaths ...
...d cigarette packets, McDonald's wrappers and even ...g Kong's far north, home to what remains of the te...e border in China, factories belch smoke into the ...llution is one of the biggest problems facing the ...
...ers at the La Jolla Institute for Allergy & Immuno... eventually lead to a new therapeutic approach for...ch as rheumatoid arthritis, colitis, psoriasis and... the body, in regulating inflammation. In the...
... be spending $33 million to add about 200 mental h...umatic stress disorder and other mental health nee...sychological effects of war have increased," conce...time military is not adequate for a nation that's ...
Other Medicine News:Health News:Hormone Therapy An Alternative to Chemotherapy for Ovarian Cancer 2Health News:Fears Of Spread Of TB After Students Death 2Health News:The Long Wait ... Dying for Lack of Kidneys 2Health News:The Long Wait ... Dying for Lack of Kidneys 3Health News:The Long Wait ... Dying for Lack of Kidneys 4Health News:Hong Kong Choked by Growing Pollution Problem 2Health News:Hong Kong Choked by Growing Pollution Problem 3Health News:New Therapeutic Approach for Autoimmune and Inflammatory Diseases 2Health News:US Army to Recruit More Psychiatrists to Counsel Stressed Out Soldiers 2Health News:US Army to Recruit More Psychiatrists to Counsel Stressed Out Soldiers 3
EpiTrain
...he therapeutic benefits of controlled compression ... minimize pain. The cuff is anatomically designed ...therapy. The Elbow Cryo/Cuff is available in an ad.../Cuffs can be ordered as a single cuff, or with a ...
...e is designed to add the therapeutic effects of cr...old separately). When inserted into the PneumaticW...ds the foot and ankle with soothing cold and compr...n.,All Cryo/Cuffs can be ordered as a single cuff...
...support helps reduce swelling and minimize pain wh...apply - it slips on like a sock, and its slim desi...spiral stays that move with the ankle, and provide...xcellent support for light sports and exercise act...
Medicine Products: